Gilead Sciences (NASDAQ: GILD)
Gilead Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Gilead Sciences Company Info
Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.
News & Analysis
History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%
This biotech stock could be poised for a nice rebound if analysts are right.
Why Gilead Sciences Stock Dropped Today
Gilead missed revenue estimates with its latest quarter and issued underwhelming 2024 guidance.
2 Beaten-Down Dividend Stocks to Buy Hand Over Fist
These stocks aren't value traps.
Why Gilead Sciences Stock Got Mashed on Monday
A late-stage trial of an otherwise successful cancer drug failed to produce the desired results.
20 High-Yield Dividend Stocks to Buy in 2024
A list of high-yielding dividend stocks to consider buying now.
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
There's no time like the present to buy these stocks.
Top ETFs Tracking CRISPR Gene Editing
These exchange-traded funds track companies in this biotech space.
Investing in Biotech ETFs
Here are the five best biotech ETFs to invest in right now.
Valuation
Podcast Episodes
What Happened With CAR-T Stocks in 2018
Here’s how CAR-T therapies did in their first full year on the market.
Should You Stick With Gilead Sciences?
Declining sales increase the stakes for Gilead's most-promising R&D projects.
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
Celgene vs. Gilead Sciences: Who Reported Better Earnings?
Celgene's and Gilead Sciences’ Q2 2017 results are fueling gains in their stock prices, but is one of these stocks doing better than the other?
Earnings Transcripts
Gilead Sciences (GILD) Q4 2023 Earnings Call Transcript
GILD earnings call for the period ending December 31, 2023.
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2023.
Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript
GILD earnings call for the period ending June 30, 2023.
Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript
GILD earnings call for the period ending March 31, 2023.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.